MPH Mittelständische Pharma Holding AG: First quarter 2017

Berlin (pta044/28.04.2017/17:45 UTC+2) Preliminary IFRS-Result, period loss - EUR 2.39 million. Equity EUR 211.56 million and thereby EUR 4.94 per share. Publication of the annual report 2016 on April, 28, 2017.

MPH Mittelständische Pharma Holding AG, Berlin (ISIN: DE000A0L1H32), announces the preliminary IFRS result for the first quarter of 2017. In the first quarter of 2017, the preliminary IFRS loss for the period was EUR -2.39 million. The reason for the loss in the period is the lower share price level of the shareholdings on March 31, 2017, compared to the share prices on December 31, 2016.

"We are positively assessing the operating performance in the first quarter of 2017 of HAEMATO AG, M1 Kliniken AG and CR Capital Real Estate AG. We are confident about the further development in 2017 despite the short-term decline in the share price. It remains the case that the Management Board proposes an unchanged dividend compared to last year, which is 12 cents per share, at the Annual General Meeting, "said Patrick Brenske and Dr. Christian Pahl, MPH Board Members.

On this day MPH will publish the annual report 2016 on the website. As already provisionally announced, the annual net profit for the year of MPH amounted to EUR 80.1 million for the financial year 2016.

About MPH Mittelständische Pharma Holding AG:

MPH Mittelständische Pharma Holding AG was founded in November 2008. Since September 2009, the company is listed on the Frankfurt Stock Exchange. MPH AG is an investment company with the strategic focus on the acquisition, construction and sale of companies. Our investment focus is on fast-growing insurance and private financed segments of the healthcare market. This includes both, the market for special medicaments for chronic diseases and medical treatments with a high proportion of self-pay, such as, for example, in the field of beauty medicine. For all investments, the requirement of a low-cost supply - usually price leadership - is at the highest quality.

(end)

Emitter:	MPH Mittelständische Pharma Holding AG Grünauer Straße 5 12557 Berlin Germany
Contact Person:	MPH AG - Investor Relations
Phone:	+49 30 8973086-60
E-Mail:	ir@mph-ag.de
Website:	www.mph-ag.de
ISIN(s):	DE000A0L1H32 (Share)
Stock Exchange(s):	Free Market in Berlin, Dusseldorf, Frankfurt (Basic Board), Stuttgart, Tradegate